Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 16/20 | 0.77 |
| ▸ | EDNRA | P25101 | 6/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6312676 | 0.92 | EDNRB (0.80) | EDNRBEDNRA | |
| SCHEMBL6321016 | 0.91 | EDNRB (0.77) | EDNRBEDNRA | |
| SCHEMBL8798525 | 0.89 | EDNRB (0.61) | EDNRBEDNRA | |
| SCHEMBL795880 | 0.87 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL6315280 | 0.84 | EDNRB (0.77) | EDNRBEDNRA | |
| SCHEMBL6314775 | 0.82 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL8798670 | 0.81 | EDNRB (0.63) | EDNRBEDNRA | |
| SCHEMBL8578754 | 0.80 | EDNRB (0.83) | EDNRBEDNRAKDM4EALDH1A1 | |
| SCHEMBL8578004 | 0.80 | EDNRB (0.86) | EDNRBEDNRA | |
| SCHEMBL8798374 | 0.79 | EDNRB (0.64) | EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| US-5731321-A | Endothelin receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-03-24 | — | — | US | claimed |
| EP-0757039-A1 | Endothelin receptor antagonists | MERCK PATENT GmbH (DE) | 1997-02-05 | — | — | EP | claimed |
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885KDM4E 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.